Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by Moonshiner592on Feb 11, 2020 11:04am

98 Views

Post# 30673892

RE:RE:Not bashing asking simple questions that investors are askin

Looking4Doubles wrote:

edrose wrote: Yes results are great but they can’t start phase3 since no money it’s that simple
its either they hit homerun with great deal and sp goes up to .06 or they can’t finish study and get product approved and patients continue to suffer

The company has already CLEARLY stated they were pursuing a licensing deal and based on their Dec announcements they already have 1 or multiple term sheets to work from. Since this topic has been brought up numerous times from bashers with "NO" recognition of licensing discussions which are OBVIOUSLY going on, I have to assume if it looks like a duck, acts like a duck and talks like a duck . . . it's IS a duck !

Take a bow Doubles!

Bullboard Posts

How a junior advances one of the largest undeveloped diamond projects